Payment overview · 2025
General Payments
$396.02
18 reported records · 9 companies
Healthcare provider profile · identity verified
Andrew Wade Walters, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TRUMANN, AR · NPI 1659638625
Verified facts
What the public records show
CMS Open Payments records show Andrew Wade Walters, M.D. received $396.02 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Onglyza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.35 | 41.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.62 | 12.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.06 | 11.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.45 | 7.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.68 | 7.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.51 | 5.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.00 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.35 | 5.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.00 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.02 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $165.35 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.62 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.06 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.68 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 126 |
| Lisinopril | Lisinopril | 523 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 487 | 101 |
| Gabapentin | Gabapentin | 468 | 87 |
| Omeprazole | Omeprazole | 405 | 76 |
| Metformin Hcl | Metformin Hcl | 348 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 67 |
| Losartan Potassium | Losartan Potassium | 290 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 48 |
| Trazodone Hcl | Trazodone Hcl | 226 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 222 | 43 |
| Meloxicam | Meloxicam | 219 | 52 |
| Potassium Chloride | Potassium Chloride | 219 | 45 |
| Furosemide | Furosemide | 218 | 60 |
| Diclofenac Sodium | Diclofenac Sodium | 208 | 49 |
| Buspirone Hcl | Buspirone Hcl | 200 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 35 |
| Eliquis | Apixaban | 160 | 27 |
| Carvedilol | Carvedilol | 158 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 29 |
| Alendronate Sodium | Alendronate Sodium | 142 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 25 |
| Jardiance | Empagliflozin | 119 | 16 |
| Januvia | Sitagliptin Phosphate | 113 | 16 |
| Simvastatin | Simvastatin | 113 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 26 |
| Mirtazapine | Mirtazapine | 99 | 22 |
| Sertraline Hcl | Sertraline Hcl | 96 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 17 |
| Allopurinol | Allopurinol | 93 | 20 |
| Montelukast Sodium | Montelukast Sodium | 91 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 11 |
| Celecoxib | Celecoxib | 75 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 12 |
| Finasteride | Finasteride | 71 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 11 |
| Pregabalin | Pregabalin | 67 | suppressed |
| Fenofibrate | Fenofibrate | 66 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 18 |
| Ezetimibe | Ezetimibe | 64 | 15 |
| Nifedipine Er | Nifedipine | 63 | 14 |
| Linzess | Linaclotide | 61 | 12 |
| Ozempic | Semaglutide | 60 | 11 |
| Glipizide | Glipizide | 59 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 11 |
| Spironolactone | Spironolactone | 59 | 14 |
| Famotidine | Famotidine | 58 | 13 |
| Lovastatin | Lovastatin | 58 | 12 |
| Atenolol | Atenolol | 57 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Propranolol Hcl | Propranolol Hcl | 54 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 11 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 17 |
| Sucralfate | Sucralfate | 35 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Prednisone | Prednisone | 25 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Digoxin | Digoxin | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Nystatin | Nystatin | 24 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Onglyza | Saxagliptin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.02 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, GVOKE HYPOPEN, LEQVIO, NURTEC ODT, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error